Cash Equivalents - Devyser Diagnostics AB (STO:DVYSR) - Alpha Spread
D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 117.5 SEK 0.43% Market Closed
Market Cap: 1.9B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Devyser Diagnostics AB
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Devyser Diagnostics AB
Cash Equivalents Peer Comparison

Comparables:
BIOG B
BONEX
VITR
SOBI
BIOA B

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
D
Devyser Diagnostics AB
STO:DVYSR
Cash Equivalents
kr262.9m
CAGR 3-Years
216%
CAGR 5-Years
103%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Cash Equivalents
kr1.5B
CAGR 3-Years
2%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Cash Equivalents
kr114.6m
CAGR 3-Years
-28%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Cash Equivalents
kr853m
CAGR 3-Years
-10%
CAGR 5-Years
14%
CAGR 10-Years
28%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Cash Equivalents
kr779m
CAGR 3-Years
50%
CAGR 5-Years
-8%
CAGR 10-Years
4%
BioArctic AB
STO:BIOA B
Cash Equivalents
kr611.6m
CAGR 3-Years
-15%
CAGR 5-Years
-8%
CAGR 10-Years
N/A

See Also

What is Devyser Diagnostics AB's Cash Equivalents?
Cash Equivalents
262.9m SEK

Based on the financial report for Dec 31, 2023, Devyser Diagnostics AB's Cash Equivalents amounts to 262.9m SEK.

What is Devyser Diagnostics AB's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
103%

Over the last year, the Cash Equivalents growth was -28%. The average annual Cash Equivalents growth rates for Devyser Diagnostics AB have been 216% over the past three years , 103% over the past five years .

Back to Top